The Adipokine Visfatin is Markedly Elevated in Obese Children

Department of Clinical Pharmacology, Medical University of Vienna, Austria.
Journal of pediatric gastroenterology and nutrition (Impact Factor: 2.63). 11/2006; 43(4):548-9. DOI: 10.1097/01.mpg.0000235749.50820.b3
Source: PubMed


The insulin-mimetic adipocytokine visfatin has been linked to adiposity and the metabolic syndrome.
Cross-sectional study.
Eighty-three nondiabetic obese children and 40 healthy controls.
We analyzed plasma visfatin concentrations to assess whether this adipokine is associated with adiposity.
Plasma visfatin concentrations were nearly 2-fold higher in obese children (mean, 1.1 ng/mL; 95% CI, 0.2-6.6) than in controls (0.6 ng/mL, 95% CI, 0.6 to 0.6; P < 0.001). No relationship was detectable between visfatin and other subject characteristics, hsCRP or the lipid profile.
Visfatin may be involved in the development of metabolic derangements in obese children.

Download full-text


Available from: Daniel Weghuber, Mar 08, 2014
    • "Many research results highlight the importance of the role of visfatin in the metabolism, especially in the regulation of energy homeostasis. For example, exposing adipocytes to glucose in vitro leads to the secretion of visfatin; likewise, in humans, the secretion of visfatin by adipocytes is influenced by glucose blood level (Haider et al., 2006a,b) and it is thus not surprising that obesity is also associated with increased circulating visfatin concentration (Filippatos et al., 2007; Haider et al., 2006a,b; Zahorska-Markiewicz et al., 2007). Very importantly, visfatin modulates glucose homeostasis by regulating insulin secretion in cells as a systemic NAD biosynthetic enzyme (Revollo et al., 2007). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Visfatin (PBEF/Nampt) is an adipocytokine that exerts pleiotropic effects within the human body, particularly affecting its metabolism and immunity. Visfatin was originally identified as being secreted by peripheral blood lymphocytes acting as a pre-B-cell colony-enhancing factor (PBEF). However, it was subsequently reported to be expressed in almost every tissue of the human body, with visceral fat deposits being the main source of visfatin. In addition to its secreted form, visfatin may also be found intracellularly where it functions as a nicotinamide phosphoribosyltransferase (Nampt). Visfatin maternal plasma concentrations increase during pregnancy, suggesting its important role in this complicated process. Alterations in visfatin level also take place in patients during pregnancy complications. This review focuses on the ones that most commonly occur in connection with visfatin: preterm labor, pre-eclampsia and gestational diabetes mellitus. The review aims to provide a better understanding of the role of visfatin during pregnancy and the causes of its alteration in maternal plasma, highlighting the potential use of visfatin as a diagnostic marker of pregnancy complications in the future.
    Journal of Reproductive Immunology 10/2015; 112:102-110. DOI:10.1016/j.jri.2015.09.004 · 2.82 Impact Factor
  • Source
    • "Visfatin is a protein secreted by visceral adipose tissue and has insulin-like metabolic effects on glucose metabolism [8]. Studies found that serum visfatin levels are increased in individuals with abdominal obesity and correlate strongly with the amount of visceral adipose tissue in humans [9,10]. The observed increase of visfatin in obesity may be a counterregulation preventing further glucose increase. "
    [Show abstract] [Hide abstract]
    ABSTRACT: This study is to determine if Adenovirus type 36 (Ad36) infection is related to macrophage infiltration in the obese group and non-obese group and the related molecular mechanisms. Ninety obesity patients and 95 non-obesity Uygur individuals were enrolled in this study. CD68 levels in abdominal subcutaneous and omental adipose tissues were detected by immunohistochemistry. The cytokine expression levels of adiponectin (APMI) and visfatin in serum were measured by enzyme-linked immunosorbent assay. Infection of 3T3-L1 cells with Ad36 was performed. Real-time PCR was performed to determine expression levels of APMI and Visfatin genes in the 3T3-L1 preadipocytes infected with Ad36. In the obese individuals infected with Ad36, the expression levels of adiponectin and visfatin in serum was elevated. For the individuals infected with Ad36, the macrophage infiltration (as indicated by CD68 level) in the obese group was also significantly higher than that in the non-obese group (P < 0.05) in both abdominal subcutaneous and omental adipose tissues. The real-time PCR results indicated that APMI mRNA levels and Visfatin mRNA levels in Ad36 infected cells were significantly increased. Ad36 infection may be a factor related with macrophage infiltration in adipose tissues of the obese patients. The APMI and Visfatin genes may be involved in the mechanism underlying the effect of Ad36 infection on the obese patients.Virtual Slides: The virtual slide(s) for this article can be found here:
    Diagnostic Pathology 04/2014; 9(1):83. DOI:10.1186/1746-1596-9-83 · 2.60 Impact Factor
  • Source
    • "In addition, visfatin had effects on lipid homeostasis similar to that of insulin and it was also involved in adipocyte proliferation and differentiation and triglyceride (TG) metabolism (2). Based on this knowledge, circulating visfatin levels and its determinants have been investigated in several clinical studies (3,4,5,6,7,8,9,10). The aim of this study was to determine the relation between serum visfatin levels and adiposity in obese and non-obese adolescents. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Visfatin, an adipokine, has insulin-mimetic effects. The main determinants of both the production and the physiologic role of visfatin are still unclear. The aim of this study is to determine the relation of serum visfatin to adiposity and glucose metabolism. 40 pubertal adolescents (20 females, 20 males; age range: 9-17 years) with exogenous obesity and 20 age- and sex-matched healthy adolescents (10 females, 10 males) were enrolled in the study. Oral glucose tolerance test (OGTT) was performed in the obese group. Serum glucose, insulin and visfatin levels were analyzed in the fasting state in the controls and at 0, 60 and 120 minutes during the OGTT in the obese group. The obese group had higher serum visfatin levels than the control group [11.6 (3.3-26) ng/mL vs. 7.5 (3.3-10.5) ng/mL, p<0.001[. Visfatin levels were correlated positively with body mass index, waist/hip ratio, insulin, and homeostasis model assessment for insulin resistance and negatively with glucose/insulin ratio in the combined group (obese subjects plus controls). Visfatin levels were essentially similar in obese subjects with and without insulin resistance (p>0.05). Serum visfatin levels did not change at 60 and 120 minutes of the OGTT compared to the baseline levels (p>0.05). Serum visfatin levels are elevated in obese adolescents and do not change with acute changes in glucose metabolism. Visfatin levels are related with adiposity and glucose metabolism parameters. However, the role and contribution of adiposity and glucose metabolism to the circulating visfatin levels in obese patients remain to be explored.
    Journal of Clinical Research in Pediatric Endocrinology 06/2012; 4(2):76-81. DOI:10.4274/jcrpe.547
Show more